Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on May 24, 2006
A more recent version of this article appeared on July 1, 2006
Neuro Oncol 2006, DOI:10.1215/15228517-2006-006
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
8/3/234    most recent
15228517-2006-006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El Andaloussi, A.
Right arrow Articles by Lesniak, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
© Copyright 2006 by the Society for Neuro-Oncology

Received October 5, 2005
Accepted February 1, 2006

Basic and Translational Investigations

An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme

Abdeljabar El Andaloussi 1 Maciej S. Lesniak 1*

1 Section of Neurosurgery, The University of Chicago, Chicago, IL 60637

* To whom correspondence should be addressed. E-mail: mlesniak{at}surgery.bsd.uchicago.edu.


   Abstract

The subpopulation of CD4+CD25+ immunoregulatory T (Tr) cells constitutes 5%-10% of CD4+ cells in humans. These cells play a crucial role in the control of tumor immune response. In this study, we evaluated the distribution of Tr cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme and examined the difference between the brain and autologous blood with respect to Tr cells. Glioma samples from 10 patients were classified as WHO grade IV astrocytoma. Control samples were obtained from patients undergoing resection of a seizure focus. The samples were analyzed by flow cytometry to determine the frequency of Tr cells and by real-time PCR for forkhead box P3 (FOXP3) expression. We then examined the expression of CD62L, CD45RO, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and assessed the functionality of Tr cells in vitro. There was a significant difference in the number of FOXP3-expressing CD4+CD25+ T cells within glioma-infiltrating lymphocytes as compared to controls (P <0.01). This difference was further observed in studies of autologous patient blood and control blood. The expression level of FOXP3 mRNA was high in Tr cells and weak in CD4+CD25- T cells. Moreover, the expression of CD62L and CTLA-4 was elevated in glioma Tr cells as compared to that in the controls. These cells were also CD45RO positive. Functional assays confirmed the suppressive activity of Tr cells in patients with glioma. The expression of CD4+CD25+FOXP3+ T cells was significantly higher in patients with glioblastoma multiforme than in controls. This increase in the frequency of Tr cells that display suppressive activity might play a role in modulation of the immune response against glioma. In light of these findings, Tr cells may represent a potential target for immunotherapy of malignant brain tumors.

Key Words: glioma, immunotherapy, regulatory T cells, tumor-infiltrating lymphocyte







  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2006 by Society for Neuro-Oncology